G. Tennekoon

1.3k total citations
31 papers, 1.0k citations indexed

About

G. Tennekoon is a scholar working on Molecular Biology, Cellular and Molecular Neuroscience and Neurology. According to data from OpenAlex, G. Tennekoon has authored 31 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 7 papers in Cellular and Molecular Neuroscience and 4 papers in Neurology. Recurrent topics in G. Tennekoon's work include Muscle Physiology and Disorders (8 papers), Nerve injury and regeneration (4 papers) and Virus-based gene therapy research (3 papers). G. Tennekoon is often cited by papers focused on Muscle Physiology and Disorders (8 papers), Nerve injury and regeneration (4 papers) and Virus-based gene therapy research (3 papers). G. Tennekoon collaborates with scholars based in United States, Netherlands and Germany. G. Tennekoon's co-authors include Guy M. McKhann, Edel Figueiredo Barbosa‐Stancioli, John H. Griffin, Thomas R. Moench, Bruce D. Trapp, Janice E. Clements, Daniel B. Sheffer, J. Lynn Rutkowski, Donald L. Price and Opendra Narayan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and The Journal of Experimental Medicine.

In The Last Decade

G. Tennekoon

31 papers receiving 975 citations

Peers

G. Tennekoon
V. M.‐Y. Lee United States
Alka Vyas United States
David R. Kaplan United States
Coryse St. Hillaire United States
D. A. Yool United Kingdom
David DiLoreto United States
V. M.‐Y. Lee United States
G. Tennekoon
Citations per year, relative to G. Tennekoon G. Tennekoon (= 1×) peers V. M.‐Y. Lee

Countries citing papers authored by G. Tennekoon

Since Specialization
Citations

This map shows the geographic impact of G. Tennekoon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Tennekoon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Tennekoon more than expected).

Fields of papers citing papers by G. Tennekoon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Tennekoon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Tennekoon. The network helps show where G. Tennekoon may publish in the future.

Co-authorship network of co-authors of G. Tennekoon

This figure shows the co-authorship network connecting the top 25 collaborators of G. Tennekoon. A scholar is included among the top collaborators of G. Tennekoon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Tennekoon. G. Tennekoon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Finkel, Richard S., Krista Vandenborne, H. Lee Sweeney, et al.. (2019). O.42Treatment of young boys with Duchenne muscular dystrophy with the NF-κB inhibitor edasalonexent showed a slowing of disease progression as assessed by MRI and functional measures. Neuromuscular Disorders. 29. S208–S208. 2 indexed citations
2.
Finkel, Richard S., John Day, Basil T. Darras, et al.. (2019). O.40Intrathecal administration of onasemnogene abeparvovec gene-replacement therapy (GRT) for spinal muscular atrophy type 2 (SMA2): phase 1/2a study (STRONG). Neuromuscular Disorders. 29. S207–S207. 4 indexed citations
3.
Finanger, Erika, Krista Vandenborne, Richard S. Finkel, et al.. (2016). CAT-1004, an oral agent targeting NF-kB: MoveDMD trial results in Duchenne muscular dystrophy (DMD). Neuromuscular Disorders. 26. S157–S157. 1 indexed citations
4.
Bonhomme, Gabrielle R., Amy Waldman, Laura J. Balcer, et al.. (2009). Pediatric optic neuritis. Neurology. 72(10). 881–885. 57 indexed citations
5.
Lampe, Anne Katrin, Yaqun Zou, Kirsty O’Brien, et al.. (2008). Exon skipping mutations in collagen VI are common and are predictive for severity and inheritance. Human Mutation. 29(6). 809–822. 68 indexed citations
6.
Pierson, Tyler Mark, Robert A. Zimmerman, G. Tennekoon, & C. Bönnemann. (2008). Mega-Corpus Callosum, Polymicrogyria, and Psychomotor Retardation: Confirmation of a Syndromic Entity. Neuropediatrics. 39(2). 123–127. 10 indexed citations
8.
Fossom, Linda H., et al.. (1993). Increased PO glycoprotein gene expression in primary and transfected rat Schwann cells after treatment with axolemma‐enriched fraction. Journal of Neuroscience Research. 35(1). 38–45. 19 indexed citations
9.
Gutmann, David H., G. Tennekoon, Jeffery L. Cole, Francis S. Collins, & J. Lynn Rutkowski. (1993). Modulation of the neurofibromatosis type 1 gene product, neurofibromin, during Schwann cell differentiation. Journal of Neuroscience Research. 36(2). 216–223. 42 indexed citations
10.
Bharucha, Vandana A., et al.. (1993). Characterization of the cis‐acting elements of the mouse myelin P2 promoter. Journal of Neuroscience Research. 36(5). 508–519. 14 indexed citations
11.
Tennekoon, G., et al.. (1993). Homophilic adhesion of the myelin P0 protein requires glycosylation of both molecules in the homophilic pair. The Journal of Cell Biology. 122(2). 451–459. 74 indexed citations
12.
Peden, Keith, J. Lynn Rutkowski, Mark R. Gilbert, & G. Tennekoon. (1990). Production of Schwann Cell Lines Using a Regulated Oncogene. Annals of the New York Academy of Sciences. 605(1). 286–293. 11 indexed citations
13.
Rutkowski, Leszek, et al.. (1990). Evidence That Secondary Rat Schwann Cells in Culture Maintain Their Differentiated Phenotype. Journal of Neurochemistry. 54(6). 1895–1904. 18 indexed citations
14.
Schwartz, Nancy B., et al.. (1988). Reconstitution of adenosine 3′-phosphate 5′-phosphosulfate transporter from rat brain. Biochemical and Biophysical Research Communications. 155(3). 1271–1277. 8 indexed citations
15.
Narayanan, Vinodh, Edel Figueiredo Barbosa‐Stancioli, Randall R. Reed, & G. Tennekoon. (1988). Characterization of a cloned cDNA encoding rabbit myelin P2 protein.. Journal of Biological Chemistry. 263(17). 8332–8337. 45 indexed citations
16.
Trapp, Bruce D., et al.. (1987). Spatial segregation of mRNA encoding myelin-specific proteins.. Proceedings of the National Academy of Sciences. 84(21). 7773–7777. 201 indexed citations
17.
Needham, Leila K., G. Tennekoon, & Guy M. McKhann. (1987). Selective growth of rat Schwann cells in neuron- and serum-free primary culture. Journal of Neuroscience. 7(1). 1–9. 63 indexed citations
18.
Narayan, Opendra, Daniel B. Sheffer, Janice E. Clements, & G. Tennekoon. (1985). Restricted replication of lentiviruses. Visna viruses induce a unique interferon during interaction between lymphocytes and infected macrophages.. The Journal of Experimental Medicine. 162(6). 1954–1969. 102 indexed citations
19.
Tennekoon, G., et al.. (1983). Topography of cerebroside sulfotransferase in Golgi-enriched vesicles from rat brain.. The Journal of Cell Biology. 97(4). 1107–1112. 39 indexed citations
20.
Tennekoon, G., et al.. (1983). Sulfatide synthesis in mice with defective synthesis of 3′-phosphoadenosine 5′-phosphosulfate. Neuroscience Letters. 37(3). 295–299. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026